Senescence and Cytoskeletal Changes in Preeclampsia UCMSCs

Study Background and Research Question

Preeclampsia (PE) is a complex hypertensive disorder of pregnancy with significant risks for maternal and fetal health. Beyond its acute effects, PE is associated with long-term cardiovascular and metabolic consequences for both mother and child. While the etiological mechanisms are multifactorial, recent research has increasingly focused on the role of the placental microenvironment and its impact on the function of umbilical cord mesenchymal stem cells (UCMSCs). UCMSCs are vital for tissue regeneration and immunomodulation, making them a promising cell source for therapeutic applications. However, it remains unclear how PE alters UCMSC biology and what molecular pathways are disrupted in this context. The reference study (He et al., 2025) aims to dissect the cellular and molecular abnormalities in UCMSCs derived from preeclamptic pregnancies, with particular attention to senescence, cytoskeletal integrity, and mitochondrial function.

Key Innovation from the Reference Study

The central innovation of He et al. lies in the comprehensive comparison of UCMSCs from normal (UCMSCs-NOR) and preeclamptic (UCMSCs-PE) donors, integrating phenotypic, functional, and transcriptomic analyses. This work provides mechanistic insights into how the preeclamptic environment drives cellular senescence and cytoskeletal remodeling in UCMSCs, and explores pharmacological interventions to reverse these abnormalities. Notably, the study demonstrates that a senolytic combination therapy (dasatinib and quercetin) can partially restore cytoskeletal integrity and reduce senescence markers in UCMSCs-PE—a potential therapeutic avenue for improving stem cell function in PE.

Methods and Experimental Design Insights

To address their research question, the authors employed a multi-layered experimental strategy:

• Characterization of UCMSCs: Surface markers were analyzed via flow cytometry to confirm mesenchymal identity. Differentiation capacity was assessed by alizarin red and oil red O staining.
• Cell Proliferation Assays: The study relied on both the CCK8 assay and EdU-based proliferation assays to quantify DNA synthesis and proliferation rates. The EdU assay, utilizing 5-ethynyl-2'-deoxyuridine incorporation, enabled high-resolution detection of S-phase DNA synthesis without requiring harsh denaturation steps—a methodological advantage for preserving cell structure.
• Transcriptomic Profiling: RNA sequencing was performed on both UCMSCs-NOR and UCMSCs-PE, revealing differential expression patterns related to senescence, inflammation, and cytoskeletal organization.
• Functional Assays: JC-1 staining was used to assess mitochondrial membrane potential, while SA-β-gal staining identified senescent cells. Immunofluorescence visualized cytoskeletal proteins and allowed for detailed morphological comparisons.
• Senolytic Intervention: A combination of dasatinib and quercetin was tested for its ability to reduce senescence and restore cytoskeletal features in UCMSCs-PE.

Core Findings and Why They Matter

The main findings from this study have important implications for both basic and translational research:

• Altered Proliferation in PE-derived UCMSCs: UCMSCs-PE exhibited significantly reduced proliferation rates, as evidenced by both CCK8 and EdU assays. The latter method, based on 5-ethynyl-2'-deoxyuridine incorporation, provided sensitive measurement of S-phase activity and highlighted functional impairment in the PE group.
• Senescence and Mitochondrial Dysfunction: UCMSCs-PE showed increased SA-β-gal activity and impaired mitochondrial membrane potential, indicative of a pronounced senescent phenotype and metabolic compromise.
• Cytoskeletal Instability: Immunofluorescence and transcriptomic data identified perturbed expression of cytoskeletal genes and abnormal cell morphology in UCMSCs-PE.
• Therapeutic Modulation: Treatment with dasatinib and quercetin reduced senescence markers and partially restored normal cytoskeletal features, supporting the potential of senescence-targeted therapies for improving UCMSC function in PE.

Together, these results point to cellular senescence and cytoskeletal instability as central pathophysiological changes in PE-derived UCMSCs, opening new avenues for targeted intervention in regenerative medicine and maternal-fetal health.

Comparison with Existing Internal Articles

Several internal analyses have highlighted the role of advanced EdU-based cell proliferation assays in mechanistic and translational research. For example, one article discusses how EdU Imaging Kits (488) enable sensitive detection of S-phase DNA synthesis and enrich understanding of cellular senescence within disease microenvironments, paralleling the reference study’s approach. Similarly, another review emphasizes the importance of click chemistry for reproducible, morphology-preserving proliferation assays, a methodological advantage that was critical in the reference paper’s workflow. Together, these resources underline the growing utility of EdU-based techniques for high-resolution, quantitative assessment of cell proliferation and senescence in both basic and applied research.

Limitations and Transferability

While the study by He et al. provides robust multi-modal evidence linking senescence and cytoskeletal dysfunction to impaired UCMSC function in PE, several limitations are acknowledged. The sample size, though adequate for initial discovery, may limit generalizability across diverse populations. Furthermore, while the senolytic intervention improved several cellular parameters, the long-term functional consequences of such treatments require further validation. The transferability of findings to other stem cell sources or disease models should be explored in future studies. Finally, while EdU-based assays offer substantial technical advantages, they are best interpreted alongside complementary functional and molecular analyses to build a holistic picture of cellular health.

Protocol Parameters

• EdU incorporation assay: Typically, cells are incubated with 10 μM 5-ethynyl-2'-deoxyuridine for 2 hours to label S-phase cells, followed by fixation and click chemistry-based fluorescent detection; exact parameters should be tailored to cell type and proliferation rate.
• Senolytic treatment: Dasatinib (100 nM) and quercetin (10 μM) were applied for 48 hours in the reference study, but dose optimization may be required for different cell models.
• SA-β-gal staining: Cells are fixed and stained according to standard protocols, with positive cells quantified by microscopy.
• JC-1 assay for mitochondrial function: Cells are incubated with JC-1 dye for 20–30 minutes at 37°C before fluorescence measurement.

Research Support Resources

For researchers seeking to replicate or extend these workflows, the use of EdU Imaging Kits (488) (SKU K1175) provides a sensitive, non-destructive platform for quantifying S-phase DNA synthesis during cell proliferation assays. These kits leverage 5-ethynyl-2'-deoxyuridine and copper-catalyzed azide-alkyne cycloaddition (CuAAC) chemistry, supporting both fluorescence microscopy and flow cytometry applications. APExBIO’s kit streamlines the detection process while preserving cell morphology, making it well-suited for studies of UCMSC proliferation and senescence in disease research.